**SUPPLEMENTARY FILE**

**STATISTICAL ANALYSIS, SUPPLEMENTARY TABLES AND DATA**

Table S1: Subgroups based on postoperative facial dysfunction measured by HB score. Wilcoxon test was used (p (α) < 0,05)

| | Normal or mild HB I - II (n = 19) | | Severe HB IIII or > (n = 12) | | W |
|---|---|---|---|---|---|
| | Median | SD | Median | SD | p (α) |
| Anxiety | 62.5 | 26.44 | 59.375 | 26.69 | n.s. |
| Facial Dysfunction | 75 | 24.64 | 51 | 24.52 | 0.03* |
| General health | 25 | 31.43 | 43.75 | 30.93 | n.s. |
| Balance | 50 | 33.14 | 50 | 33.73 | n.s. |
| Hearing | 37 | 20.79 | 40.62 | 20.58 | n.s. |
| Energy | 58.3 | 26.68 | 66.7 | 26.77 | n.s. |
| Pain | 75 | 38.14 | 47.5 | 38.04 | 0.014* |
| Total | 52.9 | 20.4 | 54.95 | 20.67 | n.s. |

*Statistically significant after Bonferroni correction.
HB: House–Brackmann; n.s.: not significant; SD: standard deviation; W: Wilkoxon log rank test

Table S2: Subgroups based on preoperative tumor size measured by Koos classification. Wilcoxon test was used (p (α) < 0.05)

| | Koos LOW GRADE (I -II) | | Koos HIGH GRADE (III-IV) | | W |
|---|---|---|---|---|---|
| | Median | SD | Median | SD | p (α) |
| Anxiety | 62.5 | 31.25 | 59.37 | 25.10 | n.s. |
| Facial Dysfunction | 75 | 29.50 | 58.3 | 22.74 | n.s. |
| General health | 50 | 24.56 | 25 | 31.79 | n.s. |
| Balance | 33.33 | 39.00 | 52.08 | 30.28 | n.s. |
| Hearing | 31.25 | 21.52 | 40.62 | 20.23 | n.s. |
| Energy | 66.7 | 30.82 | 62.5 | 25.90 | n.s. |
| Pain | 75 | 37.73 | 75 | 37.74 | n.s. |
| Total | 59 | 26.75 | 52.9 | 18.02 | n.s. |

*Statistically significant after Bonferroni correction.
n.s., not significant; SD, standard deviation, W: Wilkoxon log rank test

Table S3: Subgroups based on postoperative complications. Wilcoxon test was used (p (α) < 0.05)

| | No postop complications | | Postop complications | | KW |
|---|---|---|---|---|---|
| | Median | SD | Median | SD | p (α) |
| Anxiety | 75 | 28.26 | 56.25 | 20.35 | n.s. |
| Facial Dysfunction | 70.85 | 27.25 | 58.3 | 17.20 | n.s. |
| General health | 50 | 30.77 | 25 | 28.64 | n.s. |
| Balance | 54.17 | 34.62 | 33.33 | 28.17 | n.s. |
| Hearing | 43.75 | 20.77 | 25 | 15.15 | n.s. |
| Energy | 66.7 | 27.70 | 50 | 24.72 | n.s. |
| Pain | 75 | 37.74 | 75 | 37.73 | n.s. |
| Total | 59.10 | 21.32 | 42.3 | 17.07 | n.s. |

W: Wilkoxon Log-Rank test
*Statistically significant after Bonferroni correction.
n.s., not significant; SD, standard deviation.

PREOPERATIVE HEARING LEVEL

Patients were assigned into four groups according to their preoperative hearing level on the hear where tumor was located, according to the classification system of the Committee on Hearing and Equilibrium of the American Academy of Otolaryngology-Head and Neck surgery (AAO-HNS) 1995: group A (n = 4) *PTA (Pure Tone Thresholds) ≤ 30 dB and SDS (Speech discrimination %) ≥ 70%;* group B (n = 5) *PTA > 30 dB, ≤ 50 dB and SDS ≥ 50%,* group C (n = 8) *PTA > 50 dB and SDS ≥ 50%,* group D (n = 14) *PTA any level and SDS < 50%.* There was not a specific trend for the domain of "hearing" into different groups, and even Kruskal-Wallis test showed no significative differences for every group.

| | AUDITORY GROUP KRUSKALL-WALLIS TEST |
|---|---|
| PANQOL TOT | 0.754 ns |
| BALANCE | 0.231 ns |
| HEARING | 0.731 ns |
| ANXIETY | 0.512 ns |
| FACIAL DYS | 0.771 ns |
| ENERGY | 0.780 ns |
| PAIN | 0.754 ns |
| GENERAL HEALTH | 0.350 ns |